Article: Lab21 to Supply AdnaGen's CE-Marked System for the Detection and Analysis of CTCs in the UK and Ireland.

Lab21 and AdnaGen AG announced that they have entered into an exclusive service and distribution agreement for AdnaGen's proprietary CE-certified circulating tumor cell diagnostic assays in the United Kingdom and Ireland.

The companies said the tests are based on the capture of circulating tumor cells (CTCs) from blood and subsequent detection of tumor-associated biomarkers.

Cancer diagnostics is a fast evolving and rapidly growing segment of in-vitro diagnostics. The high prevalence and mortality rates rank cancer amongst the world's most disabling and deadly diseases. Cancer is the second most deadly condition, affecting over 25 million people ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!